Table 2.
M12 hazard ratio† | Lower CI | Upper CI | P value | M21 hazard ratio† | Lower CI | Upper CI | P value | |
---|---|---|---|---|---|---|---|---|
G-MET vs. MET | 1.37 | 0.51 | 3.68 | 0.532 | 0.81 | 0.41 | 1.62 | 0.560 |
Sex (male vs. female) | 1.52 | 0.54 | 4.31 | 0.432 | 0.94 | 0.41 | 2.13 | 0.878 |
Race/ethnicity | ||||||||
White vs. other | 0.35 | 0.08 | 1.56 | 0.170 | 0.54 | 0.22 | 1.32 | 0.177 |
Black vs. other | 1.86 | 0.66 | 5.25 | 0.238 | 0.88 | 0.38 | 2.05 | 0.769 |
Hispanic vs. other | 1.75 | 0.64 | 4.75 | 0.274 | 1.41 | 0.70 | 2.82 | 0.336 |
Baseline continuous measures | ||||||||
Age (years) | 0.98 | 0.59 | 1.63 | 0.932 | 0.99 | 0.70 | 1.41 | 0.956 |
BMI (kg/m2) | 1.14 | 0.68 | 1.92 | 0.614 | 1.14 | 0.79 | 1.64 | 0.496 |
HbA1c (%) | 1.67 | 1.07 | 2.60 | 0.024 | 1.56 | 1.12 | 2.16 | 0.008 |
Fasting glucose (mg/dL) | 1.43 | 0.93 | 2.19 | 0.100 | 1.33 | 1.01 | 1.77 | 0.044 |
2-h glucose (mg/dL) | 1.49 | 1.01 | 2.20 | 0.045 | 1.33 | 1.01 | 1.75 | 0.042 |
Log M/I | 0.83 | 0.50 | 1.38 | 0.472 | 0.93 | 0.65 | 1.34 | 0.704 |
Log ACPRg | 0.45 | 0.25 | 0.79 | 0.006 | 0.47 | 0.32 | 0.69 | <0.001 |
Log AIRg | 0.57 | 0.36 | 0.89 | 0.014 | 0.61 | 0.45 | 0.81 | <0.001 |
Log SSCP | 0.45 | 0.26 | 0.78 | 0.004 | 0.54 | 0.37 | 0.78 | 0.001 |
Log ACPRmax | 0.61 | 0.34 | 1.11 | 0.105 | 0.61 | 0.41 | 0.91 | 0.015 |
Log AIRmax | 0.59 | 0.32 | 1.09 | 0.090 | 0.57 | 0.38 | 0.85 | 0.007 |
Log 1/FI | 0.78 | 0.47 | 1.28 | 0.321 | 0.85 | 0.59 | 1.22 | 0.385 |
IGI | 0.46 | 0.20 | 1.04 | 0.061 | 0.56 | 0.34 | 0.90 | 0.017 |
CPI | 0.45 | 0.22 | 0.93 | 0.031 | 0.53 | 0.34 | 0.83 | 0.006 |
Bold P values are statistically significant (P < 0.05). All models included a term for the treatment arm. CI, 95% confidence interval.
Per 1 SD for continuous measures. Treatment arm is adjusted for insulin sensitivity by M/I, clamp-derived β-cell function responses are adjusted for treatment arm and insulin sensitivity by M/I, and all OGTT-derived β-cell function responses are adjusted for treatment arm and insulin sensitivity by 1/FI.